Osteoporosis treatment and prevention for postmenopausal women: Current and future therapeutic options

Clinical Obstetrics and Gynecology

Volumn 56, Issue 4, 2013, Pages 711-721

  Pinkerton, Joann V ^a   Thomas, Semara ^a   Dalkin, Alan C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bazedoxifene; Bisphosphonates; Denosumab; Osteoporosis; Raloxifene; Teriparatide

Indexed keywords

ALENDRONIC ACID; AROMATASE INHIBITOR; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; CALCIUM; CATHEPSIN K INHIBITOR; CONJUGATED ESTROGEN; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; ROMOSOZUMAB; SCLEROSTIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; WNT PROTEIN; ZOLEDRONIC ACID;

ARTICLE; BONE TURNOVER; BREAST CANCER; CALCIUM INTAKE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY MENOPAUSE; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; LEG CRAMP; LIFESTYLE MODIFICATION; MASTALGIA; MYALGIA; OSSIFICATION; OSTEOCYTE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN INFECTION; SPINE FRACTURE; STEM CELL TRANSPLANTATION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; WNT SIGNALING PATHWAY;

ABSORPTIOMETRY, PHOTON; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DIETARY SUPPLEMENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RALOXIFENE; RISK FACTORS; RISK REDUCTION BEHAVIOR; VITAMIN D;

EID: 84887827583     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3182a9fb02     Document Type: Article

References (38)

1. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010; 17:25-54. quiz 55-6.
2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation. Available at: Http://www.nof.org Accessed 8 March, 2013.
3. Zhang V, Jiang X, Farukhi YZ, et al. Vitamin D and Calcium: What do we need to know?. Clin Obstet gynecol. 2013;56:654-658.
4. US Preventive Services Task Force. Screening for osteoporosis: US preventive services task force recommendation statement. Ann Intern Med. 2011;154:356-364.
5. McLeod KM, McCann SE, Horvath PJ, et al. Predictors of change in calcium intake in postmenopausal women after osteoporosis screening. J Nutr. 2007;137:1968-1973.
6. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAXs WHO Fracture Risk Assessment Tool. Available at: Http://www.shef.ac.uk/FRAX/. Accessed August 3, 2013.
7. Crandall CC, Newberry SJ, Diamant A, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. (Comparative Effectiveness Reviews, No. 53.) Summary and Discussion. Available from: Http://www.ncbi.nlm.nih.gov/books/NBK 92557. Accessed August 23, 2013.
8. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75: 392-396.
9. Lewis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of the 2007 report. J Manag Care Pharm. 2012;18:S1-15.
10. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-1565.
11. Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
12. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462-468.
13. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254.
14. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis. 2010;2:3-16.
15. Elton JL, Morgan MP, Marti S, et al. Monocytes and cd T cells control the acute phase response to intravenous zoledronate: Insights from a phase IV safety trial. J Bone Miner Res. 2013;28:464-471.
16. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med. 2013;126: 13-20.
17. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis - where do we go from here?. N Engl J Med. 2012;366:2048-2051.
18. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Fouryear results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
19. Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab. 2006;91:3941-3946.
20. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96: 1751-1761.
21. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727-2741.
22. Nelson HD, Smith ME, Griffin JC, et al. Use of medications to reduce risk for primary breast cancer: A systematic review for the US Preventive Services Task Force.Ann InternMed. 2013;158:604-614.
23. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther AdvMusculoskel Dis. 2011;3:217-282.
24. NeerRM, ArnaudCD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl JMed. 2001;344:1434-1441.
25. Nakamura T, Sugimoto T, Nakano T, et al. Randomized teriparatide (human parathyroid hormone (PTH) 1-34) once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097-3106.
26. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429-2437.
27. Pinkerton JV, Dalkin AC. Combination therapy for treatment of osteoporosis: A review. Am J Obstet Gynecol. 2007;197:559-565.
28. Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276:1389-1396.
29. Cauley JA, Robbins J, Chen Z, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
30. Simon JA, Wehren LE, Ascott-Evans BH, et al. Skeletal consequences of hormone therapy discontinuance: A systematic review. Obstet Gynecol Surv. 2006;61:115-124.
31. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999-4008.
32. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo- And active-controlled study. J Bone Miner Res. 2008;23:525.
33. Pinkerton JV, Pickar JH, Racketa J, et al. Bazedoxifene/ conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric. 2012;15:411-418.
34. Costa AG, Bilezikian JP. Sclerostin: Therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10:64-72.
35. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clinical Interventions in Aging. 2012;7:235-247.
36. Perez-Castrillon JL, Pinacho F, De Luis D, et al. Odanacatib, a new drug for the treatment of osteoporosis: Review of the results in postmenopausal women. J Osteoporos. 2010; 2010:401, 581.
37. Steinert AF, Rackwitz L, Gilbert F, et al. Concise review: The clinical application of mesenchymal stem cells for musculoskeletal regeneration: Current status and perspectives. Stem Cells Transl Med. 2012;1:237-247.
38. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18:456-462.